Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

34.52 +0.23 (+0.69%)
Streaming Delayed Price Updated: 3:22 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,748,475
Open 34.66
Bid (Size) 34.51 (35)
Ask (Size) 34.52 (15)
Prev. Close 34.28
Today's Range 34.44 - 34.73
52wk Range 28.46 - 44.71
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga
FDA Prioritizes GSK's Breakthrough Drug Jemperli for Endometrial Cancer Treatment, a First in Decades
 
Via Benzinga

Performance

YTD
-2.20%
-2.20%
1 Month
-6.13%
-6.13%
3 Month
+0.19%
+0.19%
6 Month
-1.83%
-1.83%
1 Year
-19.38%
-19.38%

More News

Read More
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
From GSK plc
Via Business Wire
Peering Into GSK's Recent Short Interest
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
Via Benzinga
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
From BELLUS Health Inc.
Via Business Wire
Could Latecomer Moderna Match Big Pharma Rivals in RSV?
Via The Motley Fool
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
Via Benzinga
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Via InvestorPlace
GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
Via Benzinga
GSK Trims Stake On Consumer Business Spin Off, Raises £804M
Via Benzinga
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
Via Investor's Business Daily
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
Via The Motley Fool
Dividend Income Update April 2023
Via Talk Markets
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Via MarketBeat
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
Via Benzinga
GSK: Add This Cheap Chip Play To Your Portfolio
Via Talk Markets
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
From HKTDC
Via ACN Newswire
A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market
Via Benzinga
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
From GSK plc
Via Business Wire
GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line
Via Investor's Business Daily
KVUE Stock: Should You Buy Into the Kenvue IPO?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.